Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Since the development of fibroblast activation protein–targeted radiopharmaceuticals, (68)Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data r...

Descripción completa

Detalles Bibliográficos
Autores principales: Koerber, Stefan A., Röhrich, Manuel, Walkenbach, Leon, Liermann, Jakob, Choyke, Peter L., Fink, Christoph, Schroeter, Cathrin, Spektor, Anna-Maria, Herfarth, Klaus, Walle, Thomas, Calais, Jeremie, Kauczor, Hans-Ulrich, Jaeger, Dirk, Debus, Juergen, Haberkorn, Uwe, Giesel, Frederik L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626373/
https://www.ncbi.nlm.nih.gov/pubmed/37678928
http://dx.doi.org/10.2967/jnumed.123.266046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626373/
https://www.ncbi.nlm.nih.gov/pubmed/37678928
http://dx.doi.org/10.2967/jnumed.123.266046

Ejemplares similares